Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|
| Revenue | $1.7M | $961.0K | $2.1M | $1.4M | $851.0K | $770.0K |
| Cost of revenue | $0 | $0 | $0 | $0 | $4.5M | $7.1M |
| Gross profit | $0 | $0 | $0 | $0 | −$3.7M | −$6.3M |
| Gross margin | 0.0% | 0.0% | 0.0% | 0.0% | -434.7% | -819.6% |
| R&D | $23.7M | $31.1M | $53.0M | $59.7M | $73.8M | $59.7M |
| Operating income | −$27.7M | −$38.6M | −$70.4M | −$87.5M | −$109.5M | −$97.5M |
| EBITDA | −$26.5M | −$37.2M | −$68.7M | −$85.1M | −$104.9M | −$90.4M |
| Net income | −$27.5M | −$37.9M | −$67.5M | −$86.3M | −$109.3M | −$97.2M |
| Net margin | -1601.3% | -3948.0% | -3162.3% | -6381.0% | -12846.8% | -12617.8% |
| EPS (diluted) | -12.44 | -11.75 | -4.26 | -2.70 | -2.95 | -2.35 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $302892 | $-0.75 | $-0.75–$-0.75 | 1 |
| 2027 | $17M | $-0.75 | $-0.75–$-0.75 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds BCEL.
No tracked institution reports a position in BCEL as of their last filing.
No one on the platform has traded BCEL yet.
| — |
| IDRAIdera Pharmaceuticals, Inc. | $0.42 | -23.04% | $0 | — |
| ONCOOnconetix, Inc. | $0.95 | -2.27% | $318764 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
@0072Mtn imagine FDA refusing an A-type meeting. This seems a stock like $BCEL or another company which I don't remember the name which ended in the centies
View on StockTwits ↗$BCEL Atreca, Inc. (NASDAQ:BCEL): A Promising Biotech Firm Navigating Challenges https://beyondspx.com/article/atreca-inc-nasdaq-bcel-a-promising-biotech-firm-navigating-challenges
View on StockTwits ↗I need help with $bcel. I invested in this biotech company some time ago. It was decided to liquidate the company. March 18 was the last regular trading day on NASDAQ, and on June 14 the company was delisted completely. It was decided to initially distribute a value of $0.05 per share, and later a performance-based distribution (should the assets sold prove valuable) of approximately ~$0.2. So far I haven't received any money and I'm wondering if it's a normal process that it takes so long. This is my first share to go into liquidation, so I would appreciate it if anyone could explain what is going on or give me a possible time frame for the first distribution. I have tried to contact the company and major shareholders and, as expected, have received no response. Thanks!
View on StockTwits ↗$BCEL Atreca, Inc. (NASDAQ:BCEL): A Promising Biotech Firm Navigating Challenges http://beyondspx.com/2024/08/05/atreca-inc-nasdaqbcel-a-promising-biotech-firm-navigating-challenges/
View on StockTwits ↗$BCEL do you want to fight ? please join us on fighting against the naked short selling by signing this petition @ change.org/p/ban-citadel-se... Can you spare a minute to help this campaign? https://www.change.org
View on StockTwits ↗$BCEL new insider buying: 1 shares. http://insiderbuyingselling.com/?t=BCEL
View on StockTwits ↗$BCEL new insider selling: 7061 shares. http://insiderbuyingselling.com/?t=BCEL
View on StockTwits ↗$BCEL new insider selling: 22951 shares. http://insiderbuyingselling.com/?t=BCEL
View on StockTwits ↗$BCEL new insider selling: 20788 shares. http://insiderbuyingselling.com/?t=BCEL
View on StockTwits ↗$BCEL covered all today - most filled at EOD. Out +63% after fees. Thankful for pump and dump chasers.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.